A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Authors

Srđan Verstovšek

Published

February 29, 2012

Abstract

Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1110557

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Authors

Srđan Verstovšek

Published

February 29, 2012

Abstract

Ruxolitinib, a selective inhibitor of Janus kinase (JAK) 1 and 2, has clinically significant activity in myelofibrosis.

Supporters

Support the authors with ResearchCoin

Journal

New England Journal of Medicine

Topics

DOI

10.1056/nejmoa1110557

Paper

Paper

Paper

Paper

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Abstract

Supporters

Journal

Topics

DOI

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Abstract

Supporters

Journal

Topics

DOI